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Background: Oral delivery of insulin is challenging and must overcome the barriers of gastric 
and enzymatic degradation as well as low permeation across the intestinal epithelium. The pres-
ent study aimed to develop a liposomal delivery system containing glycocholate as an enzyme 
inhibitor and permeation enhancer for oral insulin delivery.
Methods: Liposomes containing sodium glycocholate were prepared by a reversed-phase 
evaporation method followed by homogenization. The particle size and entrapment efficiency 
of recombinant human insulin (rhINS)-loaded sodium glycocholate liposomes can be easily 
adjusted by tuning the homogenization parameters, phospholipid:sodium glycocholate ratio, 
insulin:phospholipid ratio, water:ether volume ratio, interior water phase pH, and the hydra-
tion buffer pH.
Results: The optimal formulation showed an insulin entrapment efficiency of 30% ± 2% and 
a particle size of 154 ± 18 nm. A conformational study by circular dichroism spectroscopy 
and a bioactivity study confirmed the preserved integrity of rhINS against preparative stress. 
Transmission electron micrographs revealed a nearly spherical and deformed structure with 
discernable lamella for sodium glycocholate liposomes. Sodium glycocholate liposomes 
showed better protection of insulin against enzymatic degradation by pepsin, trypsin, and 
α-chymotrypsin than liposomes containing the bile salt counterparts of sodium taurocholate 
and sodium deoxycholate.
Conclusion: Sodium glycocholate liposomes showed promising in vitro characteristics and 
have the potential to be able to deliver insulin orally.
Keywords: liposomes, glycocholate, insulin, enzymatic degradation, oral
Introduction
Nonparenteral delivery is by far the most convenient route for drug delivery, espe-
cially when repeated or routine administration is necessary.1 However, the oral route, 
as a whole, presents a major barrier to macromolecular drugs, the oral bioavailability 
of which is invariably well below the therapeutic level.2 This limitation is especially 
pronounced for proteins and peptides because of their gastric instability, susceptibil-
ity to enzymatic degradation in the gastrointestinal tract, and low permeability across 
the intestinal epithelium.3,4 In order to improve the oral bioavailability of peptides, 
researchers have employed a variety of strategies, including enhancing permeation 
by absorption enhancers5 and cell-penetrating peptides,6 or by opening the tight junc-
tion of the epithelia,7 protection from gastric and enzymatic destabilization,8,9 and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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enhancing lymphatic absorption through uptake by M cells 
in the Peyer’s patches.10 Multiple mechanisms are usually 
employed to enhance the oral bioavailability of these drugs, 
for example, in the design of particulate or colon-specific 
delivery systems for protein and peptide drugs.11–16
Liposomes, being among the most studied particulate 
carrier systems, have shown appealing potential in enhancing 
oral bioavailability of proteins and peptides.17–19 However, the 
efficacy of conventional liposomes, mainly composed of phos-
pholipid and cholesterol, has been compromised due to the 
instability of liposomes in the gastrointestinal tract and poor 
permeability across the epithelial membrane.20   Modification 
of the composition and properties of liposomes is effective 
in improving the stability and uptake of protein and peptide 
drugs by the gastrointestinal tract.21 Recently, liposomes 
containing bile salts such as sodium deoxycholate, also called 
“bilosomes,” have shown promising potential in oral immu-
nization.22 Oral administration of bilosomes incorporating 
vaccines such as the influenza subunit vaccine and cholera 
toxin B subunit was found to create as potent an antibody 
response as an equivalent dose administered parenterally.23,24 
Hepatitis B surface antigen-loaded bilosomes produced both 
a systemic as well as a mucosal antibody response upon 
oral administration.25 It is reported that although bile salts 
act exteriorly to destabilize liposomal membranes, bile salts 
embedded in the lipid bilayers act to stabilize lipid vesicles 
against further destabilization by physiological bile salts in 
the gastrointestinal tract.26,27 On the other hand, bile salts 
presenting in the lipid bilayers of the bilosomes are assumed 
to increase the fluidity of epithelial membranes and contribute 
to enhanced permeation of the vesicles.28 These ideas sparked 
our interest in the oral delivery of protein and peptide drugs 
using liposomes containing bile salts.
In this study, we investigated the feasibility of using 
liposomes containing bile salts to enhance the oral bioavail-
ability of insulin, a model protein drug. More specifically, 
sodium glycocholate was used as a new bile salt in the 
liposomal formulation to strengthen the enzyme-inhibiting 
and permeation-enhancing effect. It is reported that sodium 
glycocholate has good permeation-enhancing properties,29 
with relatively low toxicity,30 as well as a protease-inhib-
iting effect.31 We hypothesized that liposomes containing 
sodium glycocholate would provide increased protection 
of insulin from enzymatic degradation and enhanced 
permeation across the gastrointestinal epithelium. In this 
first report, liposomes containing sodium glycocholate 
were prepared by a reversed-phase evaporation method 
and characterized in vitro.
Methods and materials
Materials
Recombinant human insulin (rhINS, 27 units/mg) was pro-
vided by Novo Nordisk (Copenhagen, Denmark). Sodium 
glycocholate was purchased from Amresco (Solon, OH). Soy-
bean phosphotidylcholine and cholesterol was supplied by 
Lipoid (Ludwigshafen, Germany). Sodium taurocholate and 
sodium deoxycholate were obtained from Sigma (Shanghai, 
China). Pepsin (Ph Eur) and trypsin (more than 6000 BAEE 
units/mg) were purchased from Sigma (Shanghai, China). 
α-chymotrypsin (more than 1500 USP units/mg) were 
obtained from BD Falcon (New Jersey, USA). A Sephadex 
G50 column was purchased from Pharmacia (Shanghai, 
China). Deionized water was prepared by a Milli-Q 
purification system (Molsheim, France). High-pressure liquid 
chromatography (HPLC) grade acetonitrile was supplied by 
Merck (Darmstadt, Germany). All other chemicals were of 
analytical grade and used as received.
Four-week-old male Kunming mice weighing 18–20 g 
were purchased from the Animal Center at the Shanghai 
University of Traditional Chinese Medicine (Shanghai, 
China) and were raised in rooms controlled at 23 ± 1°C and 
55% ± 5% relative humidity with 12-hour light/12-hour dark 
time cycles. The mice received a standard laboratory chow 
diet and tap water during acclimatization. All experimental 
protocols concerning the handling of mice were in accordance 
with the requirements of the Institutional Animal Care and 
Use Committee at Fudan University.
Preparation of insulin-loaded liposomes
rhINS-loaded liposomes containing sodium glycocholate were 
prepared by a reversed-phase evaporation method. Briefly, 
soybean phosphotidylcholine and sodium glycocholate were 
dissolved in absolute ether, into which rhINS citric-Na2HPO4 
buffer solution (pH 3.0, if not specified otherwise) was added 
drop by drop. The mixture was sonicated for 5 minutes in a 
water bath until a w/o emulsion was formed. The emulsion 
was rota-evaporated under 0.07–0.08 mPa pressure with a 
rotating speed of 50 rpm at 30°C for 20 minutes to remove 
the organic solvent. A citric acid-Na2HPO4 buffer (pH 5.6) 
was then added to hydrate the dry lipids until a homogeneous 
dispersion was formed. Finally, this dispersion was extruded 
through a high-pressure homogenizer (AH 100 D; ATS Engi-
neering Inc, Brampton, ON) to obtain the sodium glycocholate 
liposomes. Before assaying, free rhINS was removed by 
eluting the liposome dispersion through the Sephadex G50 
column, following similar procedures as described below for 
measurement of entrapment efficiency.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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To prepare rhINS-loaded liposomes containing sodium 
taurocholate or sodium deoxycholate, similar procedures 
were followed, but substituting sodium glycocholate for 
sodium taurocholate or sodium deoxycholate, and likewise 
for conventional liposomes composed of soybean phospho-
tidylcholine and cholesterol as a control. Blank liposomes 
were prepared following the same procedures without add-
ing rhINS.
Particle size analysis
Sizes of the sodium glycocholate liposomes were examined 
using a dynamic light scattering instrument (NICOMP 380 
ZLS Particle Sizing Systems; PSS, Inc, Santa Barbara, CA). 
Liposomes were placed in a disposable cuvette, and photon 
counts were collected over 5 minutes using an angle of 90° 
at 25°C. Particle size was analyzed by the ZPW388 software 
program (PSS, Inc) and expressed with intensity-based 
Gaussian distribution. The result was expressed as mean ± 
standard deviation (n = 3).
Entrapment efficiency
Entrapment efficiency of the rhINS in sodium glycocholate 
liposomes was determined after separating free rhINS from 
the liposomes using molecular exclusion chromatography 
with a 30 cm long Sephadex G50 column. Briefly, liposome 
samples were introduced into the column and subsequently 
eluted with citric acid-Na2HPO4 buffer (pH 5.6). The eluted 
fraction containing the entrapped liposomal rhINS was 
analyzed by HPLC as described below. The entrapment 
efficiency was defined as the ratio of liposome-associated 
rhINS (rhINSliposomal) to total rhINS (rhINStotal), and calculated 
as shown in Eq (1):
 
EE
rhINS
rhINS
liposomal
total
(%) % =× 100   (1)
Determination of insulin
rhINS was assayed by a reversed-phase HPLC/ultraviolet 
method.32 The Agilent 1100 series HPLC system   (Agilent 
Technologies, Inc, Santa Clara, CA) was   composed 
of a quaternary pump, a degasser, an autosampler, a 
  column heater, and a tunable ultraviolet detector. rhINS 
was separated at 25°C using a C18 column (Zorbax®, 
5 µm, 4.6 mm × 150 mm, Agilent) with a C18 precolumn 
(2 mm × 20 mm), and detected by measuring the 220 nm 
absorbance of the eluate. The mobile phase was a mixture 
of acetonitrile and 0.57% H3PO4 (adjusted to pH 2.25 with 
triethylamine) in a volume ratio of 26/74, pumped at a flow 
rate of 1.0 mL/min.
conformational stability
The conformational stability of rhINS was studied by cir-
cular dichroism spectroscopy. To prepare samples for the 
circular dichroism test, rhINS was released by disrupting the 
liposomes using 1% Triton X-100. rhINS was then separated 
from soybean phosphotidylcholine and sodium glycocholate 
using an ENVI-18 solid-phase extraction column (Supelco, 
Bellefonte, PA) to avoid interference. The separation details 
were as follows. A 1 mL sample of destabilized liposomal 
mixture was applied onto an ENVI-18 column which had 
been activated by methanol. Elution was then performed with 
1 mL aqueous methanol (40%) to wash out sodium glyco-
cholate and soybean phosphotidylcholine. After that, 60% 
aqueous methanol was added to elute the rhINS, which was 
collected and adjusted to a concentration of approximately 
20 µg/mL for the circular dichroism test. A rhINS solution 
of equal concentration, dissolved in 60% aqueous methanol, 
was used as the control. The conformational characteristics 
of the insulin released and the control were examined by 
circular dichroism on a Jasco-715 circular dichroism spec-
trophotometer (Jasco Co Ltd, Hachioji, Japan). Five scans 
were performed and averaged for each sample.
Bioactivity
rhINS solution in 0.9% NaCl solution was used as a positive 
control and 0.9% NaCl solution as a negative control. The 
control and rhINS solutions retrieved from the different for-
mulations as described earlier were injected subcutaneously 
into normal mice at a dose of 0.5 IU/kg. Blood samples were 
collected from the retro-orbital plexus before dosing and 
1 hour after dosing, and then centrifuged (without addition of 
anticoagulants) at 4000 g for 5 minutes. Serum was collected 
and blood glucose levels were determined using a glucose 
GOD-PAD kit (Shanghai Rongsheng Biotech Co Ltd, Shang-
hai, China). Bioactivity was expressed as the reduction ratio 
of postdosing to predosing blood glucose level.
Transmission electron microscopy
The morphology of the liposomes was studied by negative 
transmission electron microscopy following a standard 
  procedure.33 Briefly, a drop of liposome dispersion was 
placed on 300-mesh and carbon-coated copper grids, and 
allowed to adsorb. The surplus was removed using blotting 
paper. A drop of 1% phosphotungstic acid was added, and 
the liposomes were stained for 30−60 seconds. The stained International Journal of Nanomedicine 2011:6
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Figure 1 effects of homogenization pressure (A) and number of cycles (B) on 
recombinant  human  insulin  entrapment  efficiency  and  particle  size  of  sodium 
glycocholate liposomes, when cycles fixed at four and pressure 300 bar for each. 
Note: Data expressed as means ± standard deviations (n = 3).
Abbreviation: EE, entrapment efficiency.
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liposomes were allowed to dry in ambient conditions and 
inspected with transmission electron microscopy (JEM-1230; 
JEOL, Tokyo, Japan) at an acceleration voltage of 120 kV . 
The micrographs were recorded at a final magnification of 
60,000×.
Leakage of insulin
The leakage of rhINS from the sodium glycocholate lipo-
somes was measured by detecting the change in entrapment 
efficiency change at different time intervals. Briefly, rhINS-
loaded liposomes were suspended in pH 2.0, 5.6, and 6.8 
citric acid-Na2HPO4 buffers. The suspensions were placed 
in a 37°C water bath and shaken at 60 rpm in a reciprocal 
shaker (SHZ-C, Pudong Physical Optical Co Ltd, Shanghai, 
China) over 6 hours. At specific time intervals, the entrap-
ment efficiency of the liposomes was detected using the 
analytical method described earlier. Sink conditions were 
maintained through the study.
Protection of insulin from enzymatic  
digestion
The protective effect on rhINS-loaded sodium glyco-
cholate liposomes was studied using a dissolution tester 
(ZRS-8G; Tianda Technology Co Ltd, Tianjin, China) 
following procedures similar to those described in the 
Chinese Pharmacopoeia (2010) for dissolution testing 
by the small beaker method. Briefly, 0.5 mL of liposome 
suspension was diluted in 50 mL of digestive media 
and subjected to enzymatic degradation. The digestive 
media comprised either simulated gastric fluid (contain-
ing 1% pepsin, pH 1.2) or simulated intestinal medium 
(containing 1% trypsin, pH 6.8), or α-chymotrypsin 
solution (100 µg/mL, in phosphate buffer, pH 7.8). The 
temperature was maintained at 37 ± 1.0°C and stirred with 
a paddle at 100 rpm. At appropriate time intervals, 200 µL 
of the suspension was withdrawn and diluted with an equal 
volume of 0.1 M NaOH for simulated gastric fluid, 0.1 M 
HCl for simulated intestinal medium, and α-chymotrypsin 
solution to terminate degradation. Samples were subse-
quently treated with Triton X-100 to release rhINS from 
the liposomes, prior to HPLC assay.
statistical analysis
The results were expressed as means ± standard devia-
tions. One-way analysis of variance was performed to 
assess the significance of the differences between the data. 
Results with P , 0.05 were considered to be statistically 
significant.
Results
Preparation and characterization  
of rhINs sodium glycocholate liposomes
Sodium glycocholate liposomes were obtained easily fol-
lowing the preparative procedures similar to our previous 
report using sodium deoxycholate.34 Replacing sodium 
deoxycholate with sodium glycocholate did not lead to 
significant variation in the preparative process. The pri-
mary objective of the formulation study was to optimize the 
experimental conditions to achieve high rhINS loading and 
smaller particle size, as well as robust rhINS stability during 
preparative stress.
Figure 1 shows the effect of the homogenization param-
eters, including homogenizing pressure and number of cycles, 
on entrapment efficiency and particle size. Increasing the 
homogenization pressure from 100 to 500 bar led to a sig-
nificant decrease in particle size (from 430 nm to 100 nm), 
and a slight decrease in entrapment efficiency from 18% to International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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12% (Figure 1A). However, the efficiency of particle size 
reduction decreased when the homogenization pressure 
increased over 300 bar, thus 300 bar was used for the next 
investigation. There was no significant effect of number of 
homogenization cycles (from 2–6) on entrapment efficiency 
or particle size, although a slight decreasing trend can be 
observed (Figure 1B).
Figure 2 shows the effect of the formulation 
variables on entrapment efficiency, including soybean 
phosphotidylcholine:sodium glycocholate ratio, rhINS:soybean 
phosphotidylcholine ratio, water:ether volume ratio, pH 
value of the inner water phase, ionic strength of the hydra-
tion solution, and hydration time, when the homogenization 
parameters were maintained at 300 bar and four cycles. The 
soybean phosphotidylcholine:sodium glycocholate ratio had 
the most significant effect on entrapment efficiency, with 
a near linear increase from 3% to 25% when the soybean 
phosphotidylcholine:sodium glycocholate ratio increased 
from 1:1 to 8:1 (Figure 2A). It is obvious that when the total 
amount of soybean phosphotidylcholine and sodium glyco-
cholate was fixed, the presence of more sodium glycocholate 
in the formulation compromises the entrapment of rhINS. 
The rhINS:soybean phosphotidylcholine ratio also seemed to 
have a significant effect on entrapment efficiency (Figure 2B). 
The entrapment efficiency was 11% at a rhINS:soybean 
phosphotidylcholine ratio of 0.02:1, which doubled when 
the rhINS:soybean phosphotidylcholine ratio decreased to 
0.00125:1. During the preparation of the coarse w/o emulsion, 
rhINS is dissolved in citric acid-Na2HPO4 buffer. The pH of 
this buffer should be adjusted to ensure sufficient solubility 
and entrapment efficiency of rhINS. Comparison of entrap-
ment efficiency obtained at different pH values indicated that 
entrapment efficiency followed a bell-shaped curve, with a 
maximum at pH 7.6 (Figure 2C). However, there was no 
significant difference observed between pH 3.0 and pH 7.6. 
Therefore, a pH of 3.0 was employed due to the relatively 
high solubility of rhINS at this pH. The effects of the ionic 
strength of the hydration solution on entrapment efficiency 
are shown in Figure 2D. The maximum entrapment efficiency 
was achieved at an ionic strength of 0.6. The volume ratio of 
water:ether had a slight influence on entrapment efficiency, 
with a highest value of about 25% at 1:5. However, at the 
highest water:ether ratio of 1:3, the entrapment efficiency 
value was the smallest (below 20%, Figure 2E). The hydra-
tion time also influenced entrapment efficiency. As can be 
observed in Figure 2F, entrapment efficiency increased from 
11% to 15% (P , 0.01) as the hydration time increased from 
15 minutes to 30 minutes. A hydration time of 30 minutes 
was enough to achieve high entrapment efficiency because 
a further increase in hydration time did not lead to a further 
increase in entrapment efficiency.
Based on the results of the formulation study, the optimal 
preparative conditions were chosen as follows: 334 mg soy-
bean phosphotidylcholine and 66 mg sodium glycocholate 
(4:1, mol/mol) were dissolved in 10 mL absolute ether, into 
which 2 mL rhINS buffered solution (4 mg/mL) was added. 
The mixture was sonicated and hydrated for 30 minutes to 
obtain a sodium glycocholate liposome dispersion. Finally, 
this suspension was homogenized at 300 bar for four cycles. 
The resulting rhINS-loaded sodium glycocholate liposomes 
showed an entrapment efficiency of 30.2 ± 2.2%, drug loading 
of 120.8 ± 2.7 µg/mL, and a particle size of 154 ± 18 nm with 
a polydispersity index of 0.340 ± 0.024 (Figure 3).
conformational and bioactive stability
Far-ultraviolet circular dichroism spectroscopy is usu-
ally used as a fingerprint for the identification of various 
secondary structural elements of peptides.35 Therefore, 
it was employed as an easy tool to study the conforma-
tional stability of the rhINS. Preparative variables, such as 
homogenization pressure and number of cycles, hydration 
time, amount of soybean phosphotidylcholine and insulin, 
and volume of organic solvents volume, at their extreme 
levels, may have an impact on the conformational stability 
of rhINS. Figure 4 shows the circular dichroism spectra of 
rhINS in sodium glycocholate liposomes prepared under 
extreme conditions, including the maximum amount of 
sodium glycocholate (soybean phosphotidylcholine:sodium 
glycocholate ratio of 2:1), maximum amount of rhINS 
(rhINS:soybean phosphotidylcholine ratio of 0.0025:1), max-
imum ether volume (water:ether ratio of 1:7), the strongest 
ionic strength (1.2), and the extreme preparation conditions 
(hydration for 90 minutes; homogenization at 500 bar for 
six cycles), as well as a combination of the extreme condi-
tions. The circular dichroism spectrum of rhINS released 
from the optimal sodium glycocholate liposome formula-
tion was also recorded and compared with rhINS solution   
(Figure 4, insert).
The circular dichroism spectra for free rhINS in solu-
tion show a valley at 208 nm and a shoulder at around 
223 nm, which is characteristic of the α-helix conforma-
tion and in close agreement with the spectra obtained by 
other researchers.35,36 The ratio of θ208/θ223 can be used as 
a qualitative measure of rhINS association.34 This is due to 
the antiparallel β structure which forms when two mono-
mers dimerize. This results in an increase of θ223 without an International Journal of Nanomedicine 2011:6
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increase of θ208. The θ208/θ223 ratios of rhINS released from 
the six sodium glycocholate liposomes were within the range 
of 1.638–1.852, which was close to that of free rhINS (1.734, 
P . 0.05). Moreover, the helix ratio was 21.6%–24.5%, 
which was in good agreement with that of natural rhINS 
(23.3%, P . 0.05). Such spectral features indicated that there 
was only a minor difference between the circular dichro-
ism spectra of the sodium glycocholate liposome samples International Journal of Nanomedicine 2011:6
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prepared under different preparative conditions and that of 
the free rhINS solution.
The six sodium glycocholate liposome formulations 
prepared under extreme stress were disrupted by Triton 
X-100 to release rhINS, which was then administered to the 
mice subcutaneously at a dose of 0.5 IU/kg. Blood glucose 
levels were then determined and are shown in Table 1. No 
significant difference (P . 0.05) was observed as compared 
with free rhINS solution, ie, the positive control, where a 
53.1 ± 12.6% reduction of the initial blood glucose level 
was obtained. However, a significant difference (P , 0.01) 
was observed for both the released rhINS and the positive 
control as compared with the negative control (blank sodium 
glycocholate liposomes). Therefore, it was concluded that the International Journal of Nanomedicine 2011:6
Table 1 Blood glucose level after subcutaneous administration of 0.5 IU/kg recombinant human insulin released from different sodium 
glycocholate liposomal formulations in mice. Data expressed as means ± standard deviations (n = 6)
SG liposome formulation Blood glucose level
0 hours (mmol/L) 1 hour (mmol/L) Reduction (%)
Free rhINs solution 10.70 ± 2.71 4.96 ± 1.44 53.1 ± 12.6
Blank sgc liposomes 9.93 ± 1.59 9.76 ± 1.16 1.2 ± 6.3*
At maximum sgc amount (sPc:sgc ratio 2:1) 10.98 ± 2.74 4.61 ± 1.06 57.7 ± 3.9
At maximum rhINs:sPc ratio of 0.0025:1 10.21 ± 1.59 4.35 ± 0.50 56.9 ± 6.9
At maximum ether:water ratio of 7:1 10.09 ± 1.84 5.16 ± 1.39 49.1 ± 9.7
At the strongest ionic strength (1.2) 8.48 ± 1.17 3.83 ± 1.28 52.9 ± 20.0
At extreme homogenization conditions (500 bar, 6 cycles) 7.94 ± 1.35 3.40 ± 0.85 57.3 ± 6.4
At combination of extreme stress conditions 8.83 ± 2.2 3.78 ± 0.69 55.4 ± 11.0
Note: *P , 0.05, compared with free rhINs solution.
Abbreviations: rhINs, recombinant human insulin; sgc, sodium glycocholate; sPc, soybean phosphotidylcholine.
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bioactivity of insulin was well preserved after drug loading, 
confirming the results of the conformational study.
The optimal formulation, which was prepared at less stress, 
showed good conformational stability (Figure 4, insert) and well 
preserved bioactivity, with a hypoglycemic percentage of 45.2% 
± 6.5%, which is similar to that of the free rhINS solution.
Transmission electron microscopy
Figure 5 shows the transmission electron micrographs of the 
blank and rhINS-loaded sodium glycocholate liposomes, as 
well as the conventional liposomes. An almost spheroidal 
morphology was observed for the conventional liposomes, 
whereas a less spheroidal and deformed morphology was 
observed for both blank and rhINS-loaded sodium glyco-
cholate liposomes. This was possibly due to the deformability 
of the sodium glycocholate liposomes. The vesicular struc-
ture was discernable, and the inner lamella could be weakly 
observed for sodium glycocholate liposomes. No obvious 
changes in sodium glycocholate liposome morphology were 
observed as a result of drug loading.
Leakage of insulin
Figure 6 shows the variation in entrapment efficiency in pH 
2.0, 5.6, and 6.8 buffers over 6 hours. There was no significant 
difference (P . 0.05) in entrapment efficiencies obtained at 
different time points and different pH values. The results 
AB C
Figure 5 Transmission electron micrographs of conventional liposomes (A), blank (B), 
and recombinant human insulin-loaded sodium glycocholate liposomes (C).
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Figure 6 Leakage of recombinant human insulin from liposomes as measured by 
entrapment efficiency in buffers with different pH values.
Note: Data expressed as means ± standard deviations (n = 3).
indicate that leakage of rhINS from sodium glycocholate 
liposomes was slow within the observed time duration. 
Therefore, the effect of potential variations in entrapment 
efficiency can be ignored when interpreting the in vitro 
characterization results.
Protection of insulin against digestion  
by pepsin, trypsin, and α-chymotrypsin
After treatment with pepsin, rhINS content in the conven-
tional cholesterol liposomes was remarkably decreased 
from 100% to less than 5% of the initial value after 4 hours 
(  Figure 7A). Liposomes containing bile salts all showed some 
resistance to pepsin because less degradation of rhINS was 
observed. Sodium glycocholate provided the best protection 
of liposomal rhINS, preserving 50% of rhINS at 4 hours. 
This may be attributable to the enzyme-inhibiting ability of 
sodium glycocholate. However, surprisingly, as the amount 
of sodium glycocholate increased further, less protection of International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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(Figures 8A and 9A). Again, an increase in the amount of 
sodium glycocholate in the liposome membrane leads to 
increased enzymatic degradation (Figures 8B and 9B).
Discussion
The application of liposomes containing bile salts in the 
field of oral immunization and oral delivery of poorly 
water-soluble drugs has triggered our interest in using this 
vehicle to deliver rhINS by the oral route. To achieve better 
protection against the detrimental gastrointestinal environ-
ment, we employed sodium glycocholate, a special bile salt 
that has been reported to have both enzyme-inhibiting and 
permeation-enhancing effects.28,30 Therefore, the purpose 
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liposomal rhINS was observed (Figure 7B). As the sodium 
glycocholate:soybean phosphotidylcholine ratio in the lipo-
some formulation increased from 1:8 to 1:2, the amount of 
intact insulin decreased from 70% to 28% at 4 hours. This can 
possibly be explained by the increased flexibility of the lipid 
bilayers due to the presence of excessive amounts of sodium 
glycocholate, which may lead to the leakage of rhINS. The 
protective effect of bile salts on liposomal rhINS against 
trypsin and α-chymotrypsin was different from that against 
pepsin. Conventional liposomes showed better resistance to 
trypsin than liposomes containing sodium taurocholate or 
sodium deoxycholate (Figure 8A). However, sodium glyco-
cholate liposomes still exhibited the best protection against 
these two enzymes, preserving 67% and 81% of rhINS con-
tent at 4 hours for trypsin and α-chymotrypsin, respectively International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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of this series of studies was to provide proof of concept of 
this new glycocholate-containing vehicle and to elucidate 
the underlying mechanisms. In this first report, we focus 
on issues of encapsulation of rhINS in sodium glycocholate 
liposomes and the protective effect of this vehicle against 
enzymatic degradation in simulated in vitro models. The 
hypoglycemic as well as mechanistic studies will be reported 
in upcoming publications.
The aim of the formulation study was to obtain liposomes 
with particle sizes as small as a few hundred nanometers, 
which, as previously reported, are very important in achiev-
ing good permeation across biomembranes.37 By increasing 
the homogenization pressure, the particle size can be easily 
reduced to as low as 100 nm. However, reduction in particle 
size also leads to reduced entrapment efficiency of rhINS. 
Therefore, the homogenization pressure was finally settled at 
300 bar, resulting in a particle size of about 150 nm. Because 
the particle size can be adjusted easily using this method, we 
did not investigate the effect of other preparative variables 
on particle size.
The second goal of this formulation study was to achieve 
high rhINS loading. Through screening the critical process 
and formulation variables, an entrapment efficiency of rhINS 
in sodium glycocholate liposomes as high as 30% can be 
achieved for the optimal formulation. The objective of incor-
porating as much sodium glycocholate in the liposomes as 
possible was compromised by the fact that an excess of sodium 
glycocholate would lead to significant reduction in entrapment 
efficiency. This can be explained by the fluidizing effect of 
sodium glycocholate on the lipid bilayers, which probably 
results in leakage of rhINS. An increase in the rhINS:soybean 
phosphotidylcholine ratio was helpful to increase drug load-
ing, but was at the expense of entrapment efficiency.
rhINS may be sensitive to interfacial stress during the 
ultrasonication or homogenization process. Therefore, it is 
very important to ensure preservation of rhINS stability in 
the final product. HPLC assay gives the chemical stability 
of rhINS content, whereas, conformational studies and bio-
activity assays are usually utilized to ensure the integrity of 
rhINS.38,39 In this study, we investigated the conformational 
and bioactive stability of rhINS in liposomes prepared under 
extreme stress conditions. Both conformation, as measured 
by circular dichroism, and bioactivity was preserved. 
  Therefore, we conclude that preparative stress does not cause 
destabilization of rhINS.
The clinical potential of liposomes containing bile 
salts would depend on their integrity in the gastrointestinal 
tract in order to achieve absorption-enhancing activity and 
protection of the rhINS. Thus, it is desirable not to release 
rhINS into the gastrointestinal tract. Therefore, we evalu-
ated in vitro release for a duration of 6 hours by measuring 
the change in entrapment efficiency of sodium glycocholate 
liposomes. The pH of the release medium used in this section 
was 2, 5.6, and 6.8, which are the pH of the gastric environ-
ment, isoelectric point of rhINS, and intestinal environment, 
respectively. It is designed to evaluate the stability of the 
liposome in the gastrointestinal environment compared with 
that on the shelf; however, for protection from the enzyme 
degradation component, the pH values were settled at 1.2, 
6.8, and 7.8, which were the most appropriate pH values for 
pepsin, trypsin, and α-chymotrypsin. Stability of entrapment 
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efficiency confirmed little leakage of rhINS. However, the 
integrity of sodium glycocholate liposomes needs to be 
studied in vivo.
The bile salts used could be either sodium glycocholate, 
sodium taurocholate,20 or sodium deoxycholate.40,41 These 
three bile salts were compared to highlight the effect of 
sodium glycocholate as an enzyme inhibitor. The in vitro 
protective effect against enzymatic degradation by pepsin, 
trypsin and α-chymotrypsin, the three main proteases in the 
gastrointestinal tract, confirmed the advantage of glyco-
cholate. Moreover, the safety of sodium glycocholate was 
better. As bile salts are naturally secreted by the gall bladder, 
the sodium glycocholate concentration in our formulation 
(6.77 mM) was far lower than the toxic concentration of 
bile salts (30 mM) for destroying the integrity/viability of 
Caco-2 monolayer cells.42
Conclusion
rhINS can be loaded into sodium glycocholate liposomes 
with high efficiency by a reversed-phase evaporation method 
followed by homogenization. The sodium glycocholate 
liposome particle size can be easily adjusted by tuning the 
homogenization pressure. The stability of rhINS was well 
preserved, even at extreme stress conditions, as confirmed 
by a conformational and bioactivity study. The formulation 
prepared under optimal conditions showed an entrapment 
efficiency of 30 ± 2% and a particle size of 154 ± 18 nm. 
In vitro study of the protective effect of bile salts on liposomal 
rhINS against enzymatic degradation by pepsin, trypsin, and 
α-chymotrypsin suggest superiority of sodium glycocholate. 
It is concluded that sodium glycocholate liposomes have 
potential for use in the oral delivery of protein and peptide 
drugs.
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